Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs

by Anand Patadiya | Sep 20, 2024

First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicity Human ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024 CAMBRIDGE, MA – October 14, 2023...

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors

by Anand Patadiya | Sep 20, 2024

Clearance from U.S. Food & Drug Administration and Health Canada permits Phase I open-label dose escalation study to begin in first quarter of 2024 IL-12- based anchored immunotherapy increases immune cell infiltration into tumors while decreasing systemic...

Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model

by Anand Patadiya | Sep 20, 2024

First-in-class anchored IL-12 immunotherapy mANK-101 shows tumor growth delay in murine models as a monotherapy and in combination with platinum and anti-PD-1 Data presented at the Society for Immunotherapy of Cancer in San Diego pave the way for ANK-101 as...

Ankyra Therapeutics Announces Clinical Trial Supply Agreement with Regeneron to Evaluate ANK-101 in Combination with Libtayo® (cemiplimab) in Patients with Cutaneous Squamous Cell Carcinoma

by Anand Patadiya | Sep 20, 2024

ANK-101 is a novel first-in-class anchored IL-12 immunotherapy designed for limited anchored delivery to increase immune cell infiltration into tumors and may further increase responses to immune checkpoint inhibitors CAMBRIDGE, MA – November 13, 2023 (BUSINESSWIRE) –...

Ankyra Therapeutics Announces Pre-Clinical Research Published in December JCI Insight Demonstrating Potent Anti-Tumor Activity of Anchored IL-12 in Multiple Murine Cancer Models

by Anand Patadiya | Sep 20, 2024

Pre-clinical studies of ANK-101, an anchored IL-12 therapy, demonstrate the potential of anchored immune medicines to enhance the efficacy and safety profile of cancer immunotherapies CAMBRIDGE, MA – December 12, 2023 (BUSINESSWIRE) – Ankyra Therapeutics, an emerging...